ESR1 and osteoporosis: For example, tamoxifen, a first-generation SERM initially developed for the treatment of breast cancer, and raloxifene have shown a similar affinity for both ERα and ERβ, whereas raloxifene, a second-generation SERM developed for osteoporosis treatment, has a four-times higher affinity for ERα [106].